Press release

Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH

• Utilization of synergy effects by concentrating blister activities at one site in southern Germany
• Measure implemented as part of the adjusted growth strategy

Berlin, June 19, 2023 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, has signed a contract for the sale of all shares in Kölsche Blister GmbH. Following the acquisition of Blisterzentrum Baden-Württemberg GmbH (bbw) in January, Medios AG will in future centralize its blister business entirely at the bbw site in Magstadt, Baden-Württemberg. Medios is selling Kölsche Blister GmbH to a strategic investor from the pharmacy sector. The sale has no material effect on Medios' earnings, financial position and net assets. Sales of Kölsche Blister GmbH amounted to around €12.6 million in the 2022 financial year.

Matthias Gaertner, Chief Executive Officer (CEO) of Medios AG: “The sale of Kölsche Blister GmbH was a strategic decision. As part of our adjusted strategy, we want to strengthen our core business in Germany, among other things. Kölsche Blister GmbH will remain in the parter network of Medios and will in the future work together with the Medios group in potential strategic cooperations. In the medium term, this will result in efficiency gains in the area of patient-specific blistering."

Important events for Medios AG in the 2023 financial year:

June 21:  Ordinary Annual General Meeting 2023 – Berlin

August 14:  Half-Year Financial Report as of 30 June 2023

September 20: Berenberg and Goldman Sachs 12^th German Corporate Conference – Munich

November 14: Quarterly Statement as of 30 September 2023

November 17: Warburg "Meet the Future" – Berlin

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

Contact

Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T 800

Anna Höffken
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg
T 34

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.